SCD-411
- Generic Name
- SCD-411
Study of AM003 in Patients With Locally Advanced and Metastatic Solid Tumors
- First Posted Date
- 2024-02-14
- Last Posted Date
- 2025-01-28
- Lead Sponsor
- Aummune Ltd.
- Target Recruit Count
- 12
- Registration Number
- NCT06258330
- Locations
- 🇮🇱
Rambam Health Care Campus, Haifa, Israel
🇮🇱Hadassah Medical Center, Jerusalem, Israel
🇮🇱Sheba Medical Center, Ramat Gan, Israel
Study of the Safety of Use of Intravitreal SOK583A1 Provided in a Vial Kit
Phase 3
Completed
- Conditions
- Neovascular Age-related Macular Degeneration (nAMD)
- Interventions
- First Posted Date
- 2022-03-16
- Last Posted Date
- 2023-05-10
- Lead Sponsor
- Sandoz
- Target Recruit Count
- 36
- Registration Number
- NCT05282004
- Locations
- 🇺🇸
Sandoz Investigational Site, Lynchburg, Virginia, United States
A Study to Comparing SCD411 and Eylea® in Subjects With Wet Age-related Macular Degeneration (AMD)
Phase 3
Completed
- Conditions
- Wet Age-related Macular DegenerationNeovascular Age-related Macular Degeneration
- Interventions
- First Posted Date
- 2020-07-21
- Last Posted Date
- 2023-10-10
- Lead Sponsor
- Sam Chun Dang Pharm. Co. Ltd.
- Target Recruit Count
- 576
- Registration Number
- NCT04480463
- Locations
- 🇪🇸
SCD Research Site, Zaragoza, Spain
Comparative Study to Evaluate the Efficacy and Safety of MYL-1701P and Eylea® in Subjects With Diabetic Macular Edema (DME)
- First Posted Date
- 2018-08-01
- Last Posted Date
- 2023-03-07
- Lead Sponsor
- Mylan Pharmaceuticals Inc
- Target Recruit Count
- 355
- Registration Number
- NCT03610646
- Locations
- 🇮🇳
Mylan Investigator site, Bangalore, Karnataka, India
🇷🇺Mylan Investigator Site, Saint Petersburg, Russian Federation
🇯🇵National Hospital Organization Osaka National Hospital, Osaka, Japan
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.
© Copyright 2025. All Rights Reserved by MedPath